Earnings release
Page 1
GENOMMA LAB FOURTH QUARTER & FULL YEAR 2025
Page 2
Q4 & FY 2025 Results Genomma Lab Internacional Announces Results for the Fourth Quarter and Full Year 2025 Mexico City, February 25, 2026 – Genomma Lab Internacional, S.A.B. de C.V. (BMV: LAB B) (“Genomma” or “the Company”), today announced its results for the fourth quarter and full year 2025. All figures included herein are stated in nominal Mexican pesos and have been prepared in accordance with International Financial Reporting Standards (IFRS), unless otherwise noted. Comments from our CEO, Marco Sparvieri “2025 was a challenging year, with like-for-like sales declining -4.3% due to a weak summer beverage season in Mexico, a softer overall consumption environment in the country, and execution gaps. Q4 like-for-like sales decreased -12.9% due to the Company’s decision to significantly reduced Mexico Q4 sell-in to normalize elevated retailer inventories following two weak OTC and beverage seasons. Importantly, Q4 Mexico sell-out declined a moderate -2.2%, confirming that underlying consumer demand remains resilient. Despite topline pressure, Genomma Lab delivered a resilient year-end 23.4% EBITDA margin and maintained a healthy 107-day cash-conversion cycle, underscoring the strength of our business fundamentals, disciplined execution and cost containment across the organization. We responded decisively by unlocking MXN 1.1 billion in productivity savings to reinvest in our growth initiatives: product innovation, distribution expansion, enhanced in-store execution and stronger communication. While early 2026 will reflect higher OPEX and softer sales, we expect growth initiatives to gain traction in the second half of the year, supporting a recovery in operational leverage. 2025’s downturn was cyclical, not structural, and our fundamentals remain solid. As we rebuild momentum for our next phase of sustained growth, Genomma Lab is well-positioned to emerge stronger from this cycle.” Q4 2025 and Full Year Financial Summary The following table provides a summary of the Company’s Income Statement, in millions of Mexican pesos. Q4 2025 % sales Q4 2024 % sales var % 2025 % sales 2024 % sales var % Like-for-like Sales(1) -12.9% -4.3% Net Sales 4,017.0 100% 4,665.6 100% -13.9% 17,541.2 100% 18,606.9 100% -5.7% Gross Profit 2,449.2 61.0% 2,941.7 63.1% -16.7% 11,022.1 62.8% 11,931.0 64.1% -7.6% Operating Income 800.6 19.9% 953.1 20.4% -16.0% 3,759.6 21.4% 3,922.5 21.1% -4.2% Adjusted EBITDA(2) 886.6 22.1% 1,121.7 24.0% -21.0% 4,100.9 23.4% 4,330.3 23.3% -5.3% EBITDA(3) 886.6 22.1% 1,061.7 22.8% -16.5% 4,100.9 23.4% 4,270.3 23.0% -4.0% Net Income from Continuous Operations 319.6 8.0% 367.3 7.9% -13.0% 1,607.4 9.2% 2,091.1 11.2% -23.1% EPS from Continuous Operations 0.32 0.37 -13.0% 1.61 2.09 -23.1% (1) Like-for-like (“LFL”) Sales are Net Sales expressed in constant currency and excludes the hyperinflationary subsidiary (2) Excludes effects from discontinued operations in 2024. (3) EBITDA defined as operating income before depreciation and amortization Net Sales: Decreased by -5.7% in 2025 primarily reflecting a weak su mmer beverage season in Mexico, a softer consumption environment in the country and hyperinflationary effects. Net sales decreased -13.9% in Q4 2025 primarily due to FX headwinds and an intentional -22.1% reduction in Mexico sell -in to normalize elevated retailer inventories following two weak OTC and beverage seasons. Mexico sell -out declined a moderate -2.2% during the quarter , confirming that underlying consumer demand remains resilient. EBITDA: Reached a 23.4% margin in 2025; a +43 basis-point increase driven by successful company-wide productivity initiatives, reflecting strong operational resilience despite deleveraging pressures. EBITDA reached a 22.1% margin in Q4 2025 as lower SG&A partially offset the operational deleverage following the significant reduction in Mexico sell-in during the quarter. Net Income from Continuous Operations: Decreased by -23.1% in full year 2025 despite lower net interest expense due to higher non-cash foreign exchange losses primarily related to a -42% depreciation of the Argentine peso . Net income from continuous operations declined -13.0% in Q4 2025 despite lower net interest expense and lower non-cash exchange losses due to higher taxes.
Page 3
Q4 & FY 2025 Results Regional & Business Unit Review The following review compares regional and business unit year-over-year growth in MXN unless otherwise stated. Net sales Like-for-like(1) Net sales Like-for-like(1) Q4 2025 Q4 2024 Δ% Δ% 2025 2024 Δ% Δ% Mexico 1,788.3 2,296.9 (22.1)% (22.1)% 8,248.9 8,879.0 (7.1)% (7.1)% Latam 1,861.9 1,934.7 (3.8)% 3.9% 7,658.7 7,940.4 (3.5)% 3.6% USA 366.7 433.9 (15.5)% (5.1)% 1,633.5 1,787.6 (8.6)% (11.6)% Total Net Sales 4,017.0 4,665.6 (13.9)% (12.9)% 17,541.1 18,606.9 (5.7)% (4.3)% Beverages 446.2 584.7 (23.7)% (17.2)% 2,584.8 2,671.9 (3.3)% (1.8)% OTC 1,974.0 2,338.4 (15.6)% (18.4)% 8,443.5 9,212.2 (8.3)% (3.8)% Personal Care 1,447.7 1,593.2 (9.1)% 0.5% 5,906.7 6,198.6 (4.7)% (3.0)% Infant Nutrition 149.0 149.3 (0.2)% (0.2)% 606.1 524.1 15.7% 15.7% Total Net Sales 4,017.0 4,665.6 (13.9)% (12.9)% 17,541.1 18,606.9 (5.7)% (4.3)% (1) Like-for-like (“LFL”) Sales are Net Sales expressed in constant currency and excludes the hyperinflationary subsidiary Mexico: Net sales decreased by -7.1% in full year 2025 reflecting a challenging consumption environment and a weak summer season in the country. Net sa les decreased -22.1% in Q4 2025, driven by an intentional reduction in Mexico sell-in to normalize elevated retailer inventories following two consecutive weak OTC and beverage seasons. Mexico sell-out declined a moderate - 2.2% during the quarter , confirming that underlying consumer demand remains resilient. While Skincare and Beverage market shares remained under pressure amid increased competition and softer consumption , the Company maintained stable market share in OTC and Haircare categories. Growth initiatives in product innovation, distribution expansion, enhanced in-store execution and stronger brand communication are currently ramping -up and are expected to restore sales momen tum by the second half of 2026. The EBITDA margin expanded +174 basis points to 24.9% in full year 2025 driven by successful productivity initiatives. Q4 2025 EBITDA margin increased +22 basis points to 23.4% primarily reflecting the discontinued operations effect on the comparable base. Excluding this effect , Q4 2025 EBITDA margin would have declined -224 basis points due to a significant operati onal deleverage in the quarter. Latam (ex Arg): Net sales increased by +7.4% in full year 2025 driven by a robust sales increase in Brazil, Chile, Central America and the And ean cluster. Net sales remained flat in Q4 2025 due to the a ppreciation of the Mexican peso coupled with an underperformance of Personal Care categories in Chile, partially offset by robust growth in the rest of the countries. A new pricing strategy for Personal Care brands in Chile is in place, along with the expansion of the tradit ional channel, product innovation pipeline, and an improved in-store execution across the region for 2026. Argentina: Local currency sales increased by +39.7% in full year 2025, outperforming inflation by +8.1%, supported by solid unit share gains in Ibu 400, Treg, and Suerox. Performance was partially offset by a tough comparison base related to the prior-year government subsidy for Tarifol 1-gram. Local currency sales increased by +55.3% in Q4 2025 driven by strong execution of OTC seasonal campaigns. In Mexican pesos, net sales declined -20.1% in full year 2025 and -10.1% in Q4 2025, reflecting the -42% depreciation of the Argentine peso. Latam: EBITDA margin, including Argentina, reached 23.6% in full year 2025 and 22.8% in Q4 2025; representing decreases of -98-basis points and -102-basis points, respectively, due to hyperinflationary accounting effects. US: Local currency sales decreased by -11.6% in full year 2025 and -5.1% in Q4 2025, reflecting continued disruption in the U.S. Hispanic retail landscape . Notably, the Beverage category sell-out increased +77% in full year 2025 and +48% in Q4 2025 , underscoring the Company’s distribution expansion efforts. In Mexican pesos, n et sales declined -8.6% in full year 2025 and - 15.5% in Q4 2025, reflecting a -5.0% depreciation of the Mexican peso in full year 2025 and an +8.8% appreciation of the Mexican peso in Q4 2025. EBITDA margin remained stable at 14.7% in full year 2025 and decreased -393 basis points to 11.9% in Q4 2025 reflecting operational deleverage and higher advertising spend.
Page 4
Q4 & FY 2025 Results Working Capital & Free Cash Flow The following tables provide a summary of the Company’s working capital. Q4 2025 Q4 2024 Δ Q3 2025 Δ Receivable days 92 86 +6 100 -8 Payable days 87 94 -7 93 -6 Inventory days 102 117 -15 113 -11 CCC 107 109 -2 120 -13 Cash Conversion Cycle (CCC): reached 107 days, a 2 -day improvement driven by a 15 -day reduction in inventory days and a 7 -day decrease in payable days following the Company’s strategic destocking in Mexico. Net Income from Contin uous Operations: decreased by -23.1% in full year 2025 despite lower net interest expense due to higher non-cash foreign exchange losses primarily related to a -42% depreciation of the Argentine peso. Net income from continuous operations declined by -13.0% in Q4 2025 despite lower net interest expense and reduced non -cash exchange losses due to higher taxes. Free Cash Flow (FCF): decreased -45.5% to MXN 1,507 million on a trailing twelve-month (TTM) basis compared to the same period last year, prima rily reflecting higher capital expenditures related to growth initiatives , lower net income and higher advanced tax payments. Capital Allocation Dividends. On December 23, 2025, the Company paid a c ash dividend of MXN $0.200000 per common share, totaling MXN 200 million. Genomma Lab intends to continue making quarterly dividend payments. CAPEX: Investments in manufacturing equipment totaled MXN 224.7 million in Q4 2025. For the trailing twelve months ended December 31, 2025, Investments primarily related to the commissioning of the Company’s manufacturing capabil ities and its Distribution Center totaled MXN 547.9 million. Key Debt Ratios Debt Service Coverage Ratio: 5.1x Net Debt / EBITDA: 1.1x
Page 5
Q4 & FY 2025 Results Relevant Events Genomma Lab Internacional Announces Fourteenth Dividend Payment Conference Call Date: Thursday, February 26, 2026 Time: 12:00 p.m. ET | 11:00 a.m. Mexico City Time Webcast Registration: Genomma’s Q4 & FY 2025 Earnings Call Contact Information: Sell-side Analyst Coverage As of February 25, 2026 “LABB” is covered by 8 sell-side analysts at the following brokerages: Actinver Casa de Bolsa, Banco Itaú BBA, BBVA Bancomer, BTG Pactual US Capital, GBM Grupo Bursátil Mexicano, Grupo Financiero Banorte, J.P. Morgan Securities and Monex Grupo Financiero. About Genomma Lab Internacional, S.A.B. de C.V. is one of the leading pharmaceutical and personal care products companies in Mexico with an increasing international presence. Genomma Lab develops, sells and markets a broad range of premium branded products, many of which are leaders in the categories in which they compete in terms of sales and market share. Genomma Lab relies on the combination of a successful new product development process, a consumer-oriented marketing, a broad retail distribution network and a low-cost, highly flexible operating model. Genomma Lab’s shares are listed on the Mexican Stock Exchange under the ticker “LAB B” (Bloomberg: LABB:MM). Note on Forward-Looking Statements This report may contain certain forward-looking statements and information relating to the Company that reflect the current views and/or expectations of the Company and its management with respect to its performance, business and future events. Forward looking statements include, without limitation, any statement that may predict, forecast, indicate or imply future results, performance or achievements, and may contain words like “believe,” “anticipate,” “expect,” “envisages,” “will likely result,” or any other words or phrases of similar meaning. Such statements are subject to a number of risks, uncertainties and assumptions. We caution you that a number of important factors could cause actual results to differ materially from the plans, objectives, expectations, estimates and intentions expressed in this presentation and in oral statements made by authorized officers of the Company. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of their dates. Risks and uncertainties include, but are not limited to: risks related to the impact of the COVID19 global pandemic, such as the scope and duration of the outbreak, government actions and restrictive measures implemented in response, material delays, supply ch ain disruptions and other impacts to the business, or on the Company’s ability to execute business continuity plans as a resu lt of the COVID -19 pandemic, economic factors, such as interest rate and currency exchange rate fluctuations; competition, including technological advances, new products attained by competitors; challenges inherent in new product development; the ability of the Company to successfully execute strategic plans; the impact of business combinations and divestitures; manufacturing difficulties or delays, internally or within the supply chain; significant adverse litigation or government action, including related to product liability claims; changes to applicable laws and regulations, including tax laws; changes in behavior and spending patterns of purchasers of products and services; financial instability of international economies and legal systems and sovereign risk. A further list and descriptions of these risks, uncertainties and other factors can be found within the Company’s related fi lings with the Bolsa Mexicana de Valores. Any forward -looking statement made in this release speaks only as of the date of this release. The Company undertakes no obligation to up date or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Participants: Marco Sparvieri, CEO Antonio Zamora, CFO Christianne Ibanez, IRO Investor Relations Christianne Ibanez Daniel Suarez Tel: +52 (55) 5081-0075 investor.relations@genommalab.com InspIR Group Barbara Cano Tel: +1 (646) 452-2334 barbara@inspirgroup.com
Page 6
Q4 & FY 2025 Results GENOMMA LAB INTERNACIONAL, S.A.B. DE C.V. AND SUBSIDIARIES CONSOLIDATED STATEMENT OF INCOME For the three and twelve months ended December 31, 2025 and 2024 Thousands of Mexican pesos 2025 % Sales 2024 % Sales Δ% 2025 % Sales 2024 % Sales Δ% Net Sales 4,016,967 100.0% 4,665,574 100.0% (13.9)% 17,541,158 100.0% 18,606,903 100.0% (5.7)% Cost of goods sold (1,567,728) (39.0)% (1,723,902) (36.9)% (9.1)% (6,519,026) (37.2)% (6,675,859) (35.9)% (2.3)% Gross Profit 2,449,239 61.0% 2,941,672 63.1% (16.7)% 11,022,132 62.8% 11,931,044 64.1% (7.6)% Selling, general and administrative expenses (1,502,128) (37.4)% (1,901,420) (40.8)% (21.0)% (6,950,840) (39.6)% (7,707,227) (41.4)% (9.8)% Other income (expense) (60,560) (1.5)% 21,415 0.5% (382.8)% 29,641 0.2% 46,483 0.2% (36.2)% EBITDA 886,551 22.1% 1,061,667 22.8% (16.5)% 4,100,933 23.4% 4,270,300 23.0% (4.0)% Adjusted EBITDA 886,551 22.1% 1,121,645 24.0% (21.0)% 4,100,933 23.4% 4,330,278 23.3% (5.3)% Depreciation and amortization (85,943) (2.1)% (108,523) (2.3)% (20.8)% (341,297) (1.9)% (347,809) (1.9)% (1.9)% Income from operations 800,608 19.9% 953,144 20.4% (16.0)% 3,759,636 21.4% 3,922,491 21.1% (4.2)% Interest expense (190,679) (4.7)% (248,372) (5.3)% (23.2)% (796,699) (4.5)% (887,799) (4.8)% (10.3)% Interest income 22,842 0.6% 36,797 0.8% (37.9)% 114,020 0.7% 106,111 0.6% 7.5% Foreign exchange result (2,494) (0.1)% (16,658) (0.4)% (85.0)% (392,049) (2.2)% 113,575 0.6% (445.2)% Inflationary result from monetary position (62,214) (1.5)% (185,741) (4.0)% (66.5)% (251,283) (1.4)% (363,286) (2.0)% (30.8)% Comprehensive financing income (cost) (232,545) (5.8)% (413,974) (8.9)% (43.8)% (1,326,011) (7.6)% (1,031,399) (5.5)% 28.6% Associated company 0 0.0% 0 0.0% n.a. 0 0.0% 0 0.0% n.a. Income before income taxes 568,063 14.1% 539,170 11.6% 5.4% 2,433,625 13.9% 2,891,092 15.5% (15.8)% Income tax expense (248,427) (6.2)% (171,859) (3.7)% 44.6% (826,238) (4.7)% (799,981) (4.3)% 3.3% Net income from continuous operations 319,636 8.0% 367,311 7.9% (13.0)% 1,607,387 9.2% 2,091,111 11.2% (23.1)% Results from discontinuous operations (Marzam) 0 0.0% (538,000) (11.5)% (100.0)% 0 0.0% (597,989) (3.2)% (100.0)% Continuous and Discontinuous Net Income 319,636 8.0% (170,689) (3.7)% (287.3)% 1,607,387 9.2% 1,493,122 8.0% 7.7% Q4 12M
Page 7
Q4 & FY 2025 Results GENOMMA LAB INTERNACIONAL, S.A.B. DE C.V. AND SUBSIDIARIES CONSOLIDATED STATEMENT OF FINANCIAL POSITION As of December 31, 2025 and 2024 and September 30, 2025 Thousands of Mexican pesos 2025 2024 Δ% 2025 Δ% ASSETS Current assets Cash and equivalents and restricted fund 3,073,169 2,379,112 29.2% 2,395,557 28.3% Clients - Net 4,496,070 4,444,414 1.2% 5,029,708 (10.6)% Recoverable Taxes 1,711,020 1,492,538 14.6% 1,670,999 2.4% Other accounts receivable* 958,275 702,175 36.5% 717,832 33.5% Inventory - Net 1,840,213 2,176,087 (15.4)% 2,097,999 (12.3)% Prepaid expenses 759,767 872,205 (12.9)% 908,892 (16.4)% Total current assets 12,838,514 12,066,531 6.4% 12,820,987 0.1% Non-current assets Trademarks 5,529,886 5,926,549 (6.7)% 5,505,889 0.4% Minority Investment 144,187 0 n.a. 0 n.a. Discontinoued Operations 0 0 n.a. 0 n.a. Building, properties and equipment – Net 3,840,450 3,526,885 8.9% 3,673,566 4.5% Deferred income tax, assets and others 1,429,450 1,466,152 (2.5)% 1,555,721 (8.1)% Assets by right of use 52,119 31,686 64.5% 52,217 (0.2)% Total non-current assets 10,996,092 10,951,272 0.4% 10,787,393 1.9% TOTAL ASSETS 23,834,606 23,017,803 3.5% 23,608,380 1.0% LIABILITIES AND STOCKHOLDERS' EQUITY Current Liabilities Short-term debt and Current portion of long-term debt 2,799,290 1,364,832 105.1% 2,422,338 15.6% Suppliers 1,580,930 1,738,018 (9.0)% 1,726,852 (8.5)% Other current liabilities 2,602,850 3,277,059 (20.6)% 2,609,006 (0.2)% Income tax payable 250,040 158,509 57.7% 220,579 13.4% Total current Liabilities 7,233,110 6,538,418 10.6% 6,978,775 3.6% Non-current liabilities Long-term debt securities 3,391,027 3,187,798 6.4% 3,384,708 0.2% Long-term loans with financial institutions 1,378,678 1,877,012 (26.5)% 1,535,771 (10.2)% Deferred income tax and other long term liabilities 720,362 529,719 36.0% 703,567 2.4% Payable dividends to shareholders 0 0 n.a. 0 n.a. Total non-current Liabilities 5,490,067 5,594,529 (1.9)% 5,624,046 (2.4)% TOTAL LIABILITIES 12,723,177 12,132,947 4.9% 12,602,821 1.0% Stockholders' equity Contributed Capital 1,825,352 1,825,350 0.0% 1,825,350 0.0% Retained earnings 12,219,144 11,511,687 6.1% 12,221,794 (0.0)% Cumulative translation effects of foreign subsidiaries (1,085,045) (653,102) 66.1% (1,193,887) (9.1)% Repurchased shares - Net (1,850,360) (1,801,417) 2.7% (1,850,036) 0.0% Fair value through profit OCI 2,338 2,338 0.0% 2,338 0.0% Total Stockholders' Equity 11,111,429 10,884,856 2.1% 11,005,559 1.0% TOTAL EQUITY AND LIABILITIES 23,834,606 23,017,803 3.5% 23,608,380 1.0% As of December 31, As of September 30,
Page 8
Q4 & FY 2025 Results GENOMMA LAB INTERNACIONAL, S.A.B. DE C.V. AND SUBSIDIARIES CONSOLIDATED STATEMENT OF CASH FLOWS For the three and twelve months ended December 31, 2025 and 2024 Thousands of Mexican pesos 2025 2024 Δ% 2025 2024 Δ% Cash and cash equivalents beginning of period 2,395,557 1,829,131 31.0% 2,379,112 1,671,570 42.3% Consolidated Net Income 319,636 (170,689) (287.3)% 1,607,387 1,493,122 7.7% Charges to results with no cash flow: Depreciation and amortization 94,806 121,192 (21.8)% 379,141 359,586 5.4% Income tax 248,428 171,859 44.6% 826,239 799,981 3.3% Accrued interest and others 529,041 906,590 (41.6)% 942,802 1,659,174 (43.2)% Changes in Working Capital: Clients - Net 514,302 293,794 75.1% (379,650) (580,621) (34.6)% Recoverable VAT (39,819) 41,097 (196.9)% (222,707) 70,174 (417.4)% Inventories 228,279 39,200 482.3% 22,027 (242,703) (109.1)% Suppliers (125,202) (137,762) (9.1)% 15,380 (115,815) (113.3)% Other current assets 176,735 288,700 (38.8)% 183,486 (146,646) (225.1)% Paid income tax (356,619) (273,315) 30.5% (917,817) (808,791) 13.5% Other current liabilities (333,893) 4,013 (8420.3)% (401,749) 546,256 (173.5)% Net cash generated (used) in operating activities 1,255,694 1,284,679 (2.3)% 2,054,539 3,033,717 (32.3)% Investing activities: Investment in fixed assets (224,675) (167,576) 34.1% (547,930) (270,806) 102.3% Resources from financial instruments (4,590) (1,805) 154.3% (34,270) (53,550) (36.0)% Sales of equipment 7,733 9,274 (16.6)% 10,797 15,421 (30.0)% Other asset acquisitions (124,095) (16,090) 671.3% (170,877) (675,031) (74.7)% Interest collected 22,713 36,656 (38.0)% 113,852 106,037 7.4% Net cash generated (used) in investing activities (322,914) (139,541) 131.4% (628,428) (877,929) (28.4)% Financing activities: Payments of borrowings with financial institutions (417,686) (886,769) (52.9)% (3,830,368) (4,151,027) (7.7)% Loans with financial and securities institutions 631,908 727,219 (13.1)% 5,031,354 4,275,646 17.7% Interest paid (188,476) (233,663) (19.3)% (781,337) (858,220) (9.0)% Net Stock repurchase (324) (15,792) (97.9)% (48,943) 11,107 (540.7)% Payment of liabilities for lease (22,301) (26,893) (17.1)% (64,331) (89,728) (28.3)% Dividends paid to shareholders (195,346) (183,146) 6.7% (781,772) (778,819) 0.4% Net cash used in financing activities (192,225) (619,044) (68.9)% (475,397) (1,591,041) (70.1)% Net increase in cash and cash equivalents before foreign exchange adjustments coming from international operations and inflationary affects cash 740,555 526,094 40.8% 950,714 564,747 68.3% Foreign exchange and inflationary effects from international operations (62,943) 23,887 (363.5)% (256,657) 90,820 (382.6)% Accumulated cash flow at the end of the period 3,073,169 2,379,112 29.2% 3,073,169 2,327,137 32.1% Less - restricted fund 19,169 14,073 36.2% 19,169 14,073 36.2% Cash and cash equivalents at end of period balance for operation 3,054,000 2,365,039 29.1% 3,054,000 2,313,064 32.0% 12MQ4
Page 9
Q4 & FY 2025 Results ANNEX EXCLUSION OF IAS 29 AND IAS 21 EFFECTS For the three months and last twelve months ended December 31, 2025 and 2024 Q4 2025 Q4 2024 Δ% Inflation Effect Convertion Effect Inflation Effect Convertion Effect Q4 2025 Q4 2024 Δ% (IAS 29) (IAS 21) (IAS 29) (IAS 21) Net Sales 4,017.0 4,665.6 (13.9)% 165.2 (182.8) 196.8 (28.3) 4,034.5 4,497.0 (10.3)% EBITDA 886.6 1,061.7 (16.5)% 49.3 (55.2) 65.4 (9.8) 892.5 1,006.1 (11.3)% EBITDA Margin 22.1% 22.8% 22.1% 22.4% Net Income 319.6 367.3 (13.0)% (137.2) (17.3) (324.2) (6.0) 474.1 697.5 (32.0)% Net Margin 8.0% 7.9% 11.8% 15.5% 12M Q4 2025 12M Q4 2024 Δ% Inflation Effect Convertion Effect Inflation Effect Convertion Effect 12M Q4 2025 12M Q4 2024 Δ% (IAS 29) (IAS 21) (IAS 29) (IAS 21) Net Sales 17,541.2 18,606.9 (5.7)% 299.8 (656.6) 554.1 16.1 17,898.0 18,036.6 (0.8)% EBITDA 4,100.9 4,270.3 (4.0)% 85.1 (199.1) 176.9 5.6 4,214.9 4,087.8 3.1% EBITDA Margin 23.4% 23.0% 23.5% 22.7% Consolidated Net Income 1,607.4 2,091.1 (23.1)% (492.9) (73.2) (596.2) 4.6 2,173.5 2,682.7 (19.0)% Net Margin 9.2% 11.2% 12.1% 14.9% 2025Reported 2024 Excl. IAS 29 & 21 Excl. IAS 29 & 21Reported 2025 2024 Click here